Dean Y. Maeda
Syntrix Biosystems (United States)(US)
Publications by Year
Research Areas
Immune Cell Function and Interaction, Chemokine receptors and signaling, Cancer Immunotherapy and Biomarkers, Immune cells in cancer, Protein Tyrosine Phosphatases
Most-Cited Works
- → KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer(2019)593 cited
- → Effective combinatorial immunotherapy for castration-resistant prostate cancer(2017)539 cited
- → Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain(2001)335 cited
- → Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models(2019)266 cited
- → Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy(2019)228 cited
- → Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC(2019)191 cited
- → Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate(2003)120 cited
- → Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity(2020)94 cited
- → Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer(2022)84 cited
- Binding characteristics of the gamma-hydroxybutyric acid receptor antagonist [(3)H](2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene) ethanoic acid in the rat brain.(2001)